A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 years of age) with Eosinophilic Asthma

Trial Profile

A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 years of age) with Eosinophilic Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms BREATH
  • Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 23 May 2018 Results of a post-hoc analysis of two phase III trials (NCT01287039 and NCT01285323) assessing the proportion of Reslizumab patients who reached three levels of treatment response, presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Results of a post-hoc analysis of two duplicate BREATH trials (NCT01287039 and NCT01285323) assessing the correlations between change in eosinophil levels and Lung Function Improvement, presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Results of a post-hoc analysis of two duplicate trials (NCT01287039 and NCT01285323) assessing the association between increasing baseline blood eosinophil counts and improvements in QOL, presented at the 114th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top